These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12860251)

  • 1. Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism.
    Cohn JS; Tremblay M; Boulet L; Jacques H; Davignon J; Roy M; Bernier L
    Atherosclerosis; 2003 Jul; 169(1):63-70. PubMed ID: 12860251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E.
    Xu Y; Berglund L; Ramakrishnan R; Mayeux R; Ngai C; Holleran S; Tycko B; Leff T; Shachter NS
    J Lipid Res; 1999 Jan; 40(1):50-8. PubMed ID: 9869649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on apoE gene polymorphism in Chinese type II b hyperlipidemia].
    Zhang X; Bai H; Liu B; Fan P; Zhang R; Xu Y; Yao J; Zhu H
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Jun; 32(2):179-82. PubMed ID: 12600078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
    Campos H; Perlov D; Khoo C; Sacks FM
    J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
    Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS
    J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
    Dinkel RE; Barrett PH; Demant T; Parhofer KG
    Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
    Breyer ED; Le NA; Li X; Martinson D; Brown WV
    J Lipid Res; 1999 Oct; 40(10):1875-82. PubMed ID: 10508207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children.
    Shachter NS; Rabinowitz D; Stohl S; Conde-Knape K; Cohn JS; Deckelbaum RJ; Berglund L; Shea S
    Atherosclerosis; 2005 Apr; 179(2):387-93. PubMed ID: 15777558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL.
    Westerterp M; de Haan W; Berbée JF; Havekes LM; Rensen PC
    J Lipid Res; 2006 Jun; 47(6):1203-11. PubMed ID: 16537968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
    Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
    J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential metabolism of human VLDL according to content of ApoE and ApoC-III.
    Tomiyasu K; Walsh BW; Ikewaki K; Judge H; Sacks FM
    Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1494-500. PubMed ID: 11557678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content.
    Khoo C; Campos H; Judge H; Sacks FM
    J Lipid Res; 1999 Feb; 40(2):202-12. PubMed ID: 9925648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E polymorphism and hyperlipemia in type II diabetics.
    Eto M; Watanabe K; Iwashima Y; Morikawa A; Oshima E; Sekiguchi M; Ishii K
    Diabetes; 1986 Dec; 35(12):1374-82. PubMed ID: 3770314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study.
    Luc G; Bard JM; Arveiler D; Evans A; Cambou JP; Bingham A; Amouyel P; Schaffer P; Ruidavets JB; Cambien F
    Arterioscler Thromb; 1994 Sep; 14(9):1412-9. PubMed ID: 8068601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined effects of apoE-CI-CII cluster and LDL-R gene polymorphisms on chromosome 19 and coronary artery disease risk.
    Wang C; Zhou X; Ye S; Han D; Tan X; Zheng F; Shi Q
    Int J Hyg Environ Health; 2006 May; 209(3):265-73. PubMed ID: 16459141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.
    Cohn JS; Tremblay M; Batal R; Jacques H; Veilleux L; Rodriguez C; Bernier L; Mamer O; Davignon J
    J Lipid Res; 2002 Oct; 43(10):1680-7. PubMed ID: 12364552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression.
    Gerritsen G; Rensen PC; Kypreos KE; Zannis VI; Havekes LM; Willems van Dijk K
    J Lipid Res; 2005 Jul; 46(7):1466-73. PubMed ID: 15863838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein C-I expression in the brain in Alzheimer's disease.
    Petit-Turcotte C; Stohl SM; Beffert U; Cohn JS; Aumont N; Tremblay M; Dea D; Yang L; Poirier J; Shachter NS
    Neurobiol Dis; 2001 Dec; 8(6):953-63. PubMed ID: 11741391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein.
    Weisgraber KH; Mahley RW; Kowal RC; Herz J; Goldstein JL; Brown MS
    J Biol Chem; 1990 Dec; 265(36):22453-9. PubMed ID: 2266137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.